Treatment of latent tuberculosis infection

Michael Kessler, James Smith, Jr.

Research output: Contribution to journalArticle

Abstract

Latent tuberculosis infection (LTBI) is the most common source for active tuberculosis (TB), and its treatment remains an important cornerstone of global TB eradication. Although pregnancy may represent a unique time during which LTBI may be treated successfully, pregnancy and the postpartum period have been recognized as periods during which the risk of hepatitis from isoniazid (INH), the drug of choice for LTBI, may be increased. Thus, recommendations have suggested postponing treatment of LTBI until the postpartum period. Recent programs indicate that in properly designed surveillance programs, the risk of INH-induced hepatitis is low. Similar to other ongoing clinical encounters in which targeted LTBI screening and treatment may be accomplished, such as methadone and needle exchange clinics, antenatal clinics represent an opportunity to establish trust between clinician and patient for ongoing surveillance for complications and compliance. Furthermore, the addition of a newborn into the household where LTBI has been found poses new implications for eradication of TB. Prospective data collection on outcomes for such programs will be invaluable in assessing the efficacy of these efforts.

Original languageEnglish
JournalNeoReviews
Volume10
Issue number8
DOIs
StatePublished - 2009

Fingerprint

Latent Tuberculosis
Tuberculosis
Postpartum Period
Hepatitis
Therapeutics
Pregnancy
Methadone
Isoniazid
Compliance
Needles
Newborn Infant
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Treatment of latent tuberculosis infection. / Kessler, Michael; Smith, Jr., James.

In: NeoReviews, Vol. 10, No. 8, 2009.

Research output: Contribution to journalArticle

Kessler, Michael ; Smith, Jr., James. / Treatment of latent tuberculosis infection. In: NeoReviews. 2009 ; Vol. 10, No. 8.
@article{2043deb5be0940c1a21c64250f6c1e5e,
title = "Treatment of latent tuberculosis infection",
abstract = "Latent tuberculosis infection (LTBI) is the most common source for active tuberculosis (TB), and its treatment remains an important cornerstone of global TB eradication. Although pregnancy may represent a unique time during which LTBI may be treated successfully, pregnancy and the postpartum period have been recognized as periods during which the risk of hepatitis from isoniazid (INH), the drug of choice for LTBI, may be increased. Thus, recommendations have suggested postponing treatment of LTBI until the postpartum period. Recent programs indicate that in properly designed surveillance programs, the risk of INH-induced hepatitis is low. Similar to other ongoing clinical encounters in which targeted LTBI screening and treatment may be accomplished, such as methadone and needle exchange clinics, antenatal clinics represent an opportunity to establish trust between clinician and patient for ongoing surveillance for complications and compliance. Furthermore, the addition of a newborn into the household where LTBI has been found poses new implications for eradication of TB. Prospective data collection on outcomes for such programs will be invaluable in assessing the efficacy of these efforts.",
author = "Michael Kessler and {Smith, Jr.}, James",
year = "2009",
doi = "10.1542/neo.10-8-e396",
language = "English",
volume = "10",
journal = "NeoReviews",
issn = "1526-9906",
publisher = "American Academy of Pediatrics",
number = "8",

}

TY - JOUR

T1 - Treatment of latent tuberculosis infection

AU - Kessler, Michael

AU - Smith, Jr., James

PY - 2009

Y1 - 2009

N2 - Latent tuberculosis infection (LTBI) is the most common source for active tuberculosis (TB), and its treatment remains an important cornerstone of global TB eradication. Although pregnancy may represent a unique time during which LTBI may be treated successfully, pregnancy and the postpartum period have been recognized as periods during which the risk of hepatitis from isoniazid (INH), the drug of choice for LTBI, may be increased. Thus, recommendations have suggested postponing treatment of LTBI until the postpartum period. Recent programs indicate that in properly designed surveillance programs, the risk of INH-induced hepatitis is low. Similar to other ongoing clinical encounters in which targeted LTBI screening and treatment may be accomplished, such as methadone and needle exchange clinics, antenatal clinics represent an opportunity to establish trust between clinician and patient for ongoing surveillance for complications and compliance. Furthermore, the addition of a newborn into the household where LTBI has been found poses new implications for eradication of TB. Prospective data collection on outcomes for such programs will be invaluable in assessing the efficacy of these efforts.

AB - Latent tuberculosis infection (LTBI) is the most common source for active tuberculosis (TB), and its treatment remains an important cornerstone of global TB eradication. Although pregnancy may represent a unique time during which LTBI may be treated successfully, pregnancy and the postpartum period have been recognized as periods during which the risk of hepatitis from isoniazid (INH), the drug of choice for LTBI, may be increased. Thus, recommendations have suggested postponing treatment of LTBI until the postpartum period. Recent programs indicate that in properly designed surveillance programs, the risk of INH-induced hepatitis is low. Similar to other ongoing clinical encounters in which targeted LTBI screening and treatment may be accomplished, such as methadone and needle exchange clinics, antenatal clinics represent an opportunity to establish trust between clinician and patient for ongoing surveillance for complications and compliance. Furthermore, the addition of a newborn into the household where LTBI has been found poses new implications for eradication of TB. Prospective data collection on outcomes for such programs will be invaluable in assessing the efficacy of these efforts.

UR - http://www.scopus.com/inward/record.url?scp=77149161164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149161164&partnerID=8YFLogxK

U2 - 10.1542/neo.10-8-e396

DO - 10.1542/neo.10-8-e396

M3 - Article

VL - 10

JO - NeoReviews

JF - NeoReviews

SN - 1526-9906

IS - 8

ER -